Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Paraproteinemias × daratumumab × Clear all

Phase

Status

Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 54 Recurrence 6 Neoplasms, Plasma Cell 5 Neoplasms 3 Smoldering Multiple Myeloma 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Paraproteinemias 1 Glioblastoma 1 Disease 1 Chromosome 17 deletion 1

Interventions

Dexamethasone 2 Cyclophosphamide 2 Clinical Protocols 2 Bortezomib 2 daratumumab 1 Rifaximin 1 ARQ531 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03236428 2025-03-05

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon ⚡